Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DH0R | ISIN: GB00BD5H8572 | Ticker-Symbol: LMQ
Frankfurt
01.11.24
08:00 Uhr
0,002 Euro
-0,001
-25,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OXFORD BIODYNAMICS PLC Chart 1 Jahr
5-Tage-Chart
OXFORD BIODYNAMICS PLC 5-Tage-Chart

Aktuelle News zur OXFORD BIODYNAMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoOxford BioDynamics - Director / PDMR holdings and Total Voting Rights-
25.10.Oxford BioDynamics - Prognostic Covid Severity Test Study Published-
22.10.Oxford BioDynamics - CiRT Receives Clinical Approval from NYS CLEP-
14.10.Oxford BioDynamics pledges to cut costs amid need to raise extra funds1
14.10.Oxford Biodynamics shares plummet as company faces cliff edge1
14.10.Oxford BioDynamics - Commercial update for FY24-
07.10.Oxford BioDynamics - CIRRP Award Update-
25.07.Oxford BioDynamics, Plc: Oxford Biodynamics to present on its line of EpiSwitch products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA.187Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on the EpiSwitch 3D genomics platform...
► Artikel lesen
25.07.Oxford BioDynamics - OBD pursuing EpiSwitch as companion diagnostics1
21.06.Oxford BioDynamics - Grant of Options1
18.06.Oxford BioDynamics revenue up 49% in first half as test sales rise1
18.06.Oxford BioDynamics - Half-year Report-
06.06.Oxford BioDynamics - OBD's PSE test to be used in NCI trial-
04.06.Oxford BioDynamics Plc: Oxford BioDynamics Develops a High Accuracy, Discriminating Diagnostic Test for Multiple Canine Cancers305EpiSwitch® Specific Canine Blood (EpiSwitch® SCB) test is a new canine multi-cancer diagnostic test based on OBD's non-invasive EpiSwitch® array platform Test developed in collaboration...
► Artikel lesen
04.06.Oxford BioDynamics develops canine cancer test with 89% accuracy1
04.06.Oxford BioDynamics - OBD develops multi-cancer diagnostic test for dogs-
24.05.Oxford BioDynamics - Notice of Results-
23.05.TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact1
23.05.Oxford BioDynamics - OBD partners with Goodbody Clinic on PSE test-
21.05.Oxford BioDynamics to provide tests to largest UK charitable hospital1
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1